FY2025 Earnings Forecast for AbbVie Issued By Zacks Research

AbbVie Inc. (NYSE:ABBV - Free Report) - Zacks Research decreased their FY2025 earnings per share (EPS) estimates for shares of AbbVie in a research note issued to investors on Tuesday, April 15th. Zacks Research analyst S. Ganoria now forecasts that the company will earn $12.02 per share for the year, down from their prior forecast of $12.14. The consensus estimate for AbbVie's current full-year earnings is $12.31 per share.

A number of other research analysts have also issued reports on the company. Bank of America boosted their target price on AbbVie from $200.00 to $223.00 and gave the company a "neutral" rating in a report on Tuesday, March 4th. Citigroup increased their price target on shares of AbbVie from $205.00 to $215.00 and gave the stock a "buy" rating in a report on Monday, February 3rd. Raymond James reiterated an "outperform" rating and set a $220.00 target price (up previously from $218.00) on shares of AbbVie in a research report on Monday, February 3rd. BMO Capital Markets increased their price objective on AbbVie from $208.00 to $215.00 and gave the stock an "outperform" rating in a research report on Monday, February 3rd. Finally, Truist Financial increased their price target on shares of AbbVie from $211.00 to $217.00 and gave the company a "buy" rating in a report on Monday, February 3rd. Seven analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, AbbVie presently has a consensus rating of "Moderate Buy" and a consensus price target of $210.71.

AbbVie Stock Performance

Shares of NYSE ABBV traded down $2.79 during midday trading on Thursday, reaching $170.20. 2,378,244 shares of the company were exchanged, compared to its average volume of 5,991,301. AbbVie has a 1 year low of $153.58 and a 1 year high of $218.66. The stock has a fifty day simple moving average of $198.47 and a 200 day simple moving average of $187.71. The company has a current ratio of 0.66, a quick ratio of 0.55 and a debt-to-equity ratio of 17.94. The stock has a market cap of $301.08 billion, a P/E ratio of 70.92, a PEG ratio of 1.62 and a beta of 0.55.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.98 by ($0.82). AbbVie had a return on equity of 296.28% and a net margin of 7.59%. During the same quarter in the previous year, the business earned $2.79 EPS.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Fiduciary Advisors Inc. acquired a new position in shares of AbbVie during the 4th quarter valued at $29,000. EnRich Financial Partners LLC raised its position in AbbVie by 196.4% in the fourth quarter. EnRich Financial Partners LLC now owns 166 shares of the company's stock valued at $29,000 after purchasing an additional 110 shares during the period. Promus Capital LLC acquired a new position in shares of AbbVie during the fourth quarter worth about $30,000. Bradley & Co. Private Wealth Management LLC purchased a new stake in shares of AbbVie in the fourth quarter worth about $31,000. Finally, Prudent Man Investment Management Inc. acquired a new stake in shares of AbbVie in the fourth quarter valued at about $32,000. Hedge funds and other institutional investors own 70.23% of the company's stock.

Insider Activity

In related news, SVP Kevin K. Buckbee sold 18,944 shares of the company's stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $203.41, for a total transaction of $3,853,399.04. Following the completion of the transaction, the senior vice president now owns 11,496 shares of the company's stock, valued at approximately $2,338,401.36. This represents a 62.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Jeffrey Ryan Stewart sold 58,832 shares of the business's stock in a transaction on Monday, March 31st. The shares were sold at an average price of $210.08, for a total transaction of $12,359,426.56. Following the sale, the executive vice president now directly owns 53,234 shares of the company's stock, valued at $11,183,398.72. This represents a 52.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 113,471 shares of company stock valued at $23,426,451 in the last 90 days. 0.25% of the stock is currently owned by insiders.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be issued a $1.64 dividend. This represents a $6.56 annualized dividend and a yield of 3.85%. The ex-dividend date of this dividend is Tuesday, April 15th. AbbVie's dividend payout ratio (DPR) is 273.33%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.